0
Pipeline Programs↗
2
Active Trials↗
0
Companies Involved↗
EBV is an early-stage landscape with 0 programs across 0 companies.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
3
clinical trials
Recruiting2 · 67%
Completed1 · 33%
Clinical Trials
Trial Activity
Golidocitinib Combined With Selinexor for CAEBVD
Recruiting·—·Phase 2/3·NCT07369739·28 enrolled
The Natural History of Severe Viral Infections and Characterization of Immune Defects
Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT01011712·600 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)